Madhavan Ramya, Varghese Tintu, Eswaran Akilandeswari, Gandhi Vaishnavi, Saravanan Poornima, Raj Lakshmi, Raju Reshma, Xavier Julian Vivek Leander, Joseph Jovin Stanley, Premkumar Prasanna Samuel, Rose Winsley, John Jacob
The Wellcome Trust Research Laboratory, Christian Medical College, Vellore, India.
Department of Child Health, Christian Medical College, Vellore, India.
Am J Trop Med Hyg. 2025 Aug 12;113(4):883-887. doi: 10.4269/ajtmh.25-0069. Print 2025 Oct 1.
The mumps vaccine remains excluded from India's National Immunization Schedule (NIS) because of insufficient data on the community-level disease burden, despite mumps being a vaccine-preventable disease. In the present study, biobanked serum samples from an urban population in Vellore, stratified by age (in age groups of 1-5, 6-15, and 16-40 years) and sex, were tested for anti-mumps IgG antibodies using ELISA. The seroprevalence rates of mumps were 26%, 71%, and 84% in the 1- to 5-year, 6- to 15-year, and 16- to 40-year age groups, respectively, indicating a high burden in the community. Women in the 16- to 40-year age group exhibited a higher seroprevalence compared with males, with antibody levels consistently lower in males across both the 6- to 15-year and 16- to 40-year age groups (P <0.05). The present study highlights increasing mumps exposure with age and underscores the urgent need to include the mumps vaccine in the NIS to address the high disease burden and prevent complications.
尽管腮腺炎是一种可通过疫苗预防的疾病，但由于缺乏关于社区层面疾病负担的充分数据，腮腺炎疫苗仍未被纳入印度国家免疫规划（NIS）。在本研究中，利用酶联免疫吸附测定法（ELISA）对来自韦洛尔市城市人口的生物样本库血清样本进行检测，这些样本按年龄（1至5岁、6至15岁和16至40岁年龄组）和性别分层，以检测抗腮腺炎IgG抗体。1至5岁、6至15岁和16至40岁年龄组的腮腺炎血清阳性率分别为26%、71%和84%，表明社区负担较重。16至40岁年龄组的女性血清阳性率高于男性，在6至15岁和16至40岁年龄组中，男性的抗体水平始终较低（P<0.05）。本研究强调了随着年龄增长腮腺炎暴露增加的情况，并强调迫切需要将腮腺炎疫苗纳入国家免疫规划，以应对高疾病负担并预防并发症。
